Sublocade (buprenorphine) is a brand-name subcutaneous injection prescribed for opioid use disorder. It works to help reduce the need for opioids by acting in certain areas of the brain called mu and ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Bicycle Health, a provider of telemedicine treatment for opioid use disorder, announced that it will make prescriptions for buprenorphine extended release injections (known as Sublocade) available to ...

RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 ...

Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Indivior PLC announced that it was added to the S&P SmallCap 600 index on December 22, 2025, following earlier inclusions in the S&P 1000 and the S&P Pharmaceuticals Select Industry Index and ...

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...